Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis
Authors:
- 2 September 2013
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 73 (15) , 1636-1650
Abstract
BACKGROUND Despite an initial response to hormonal therapy, patients with advanced prostate cancer (PC) almost always progress to castration-resistant disease (CRPC). Although serum testosterone (T) is reduced by androgen deprivation therapy, intratumoral T levels in CRPC are comparable to those in prostate tissue of eugonadal men. These levels could originate from intratumoral conversion of adrenal androgens and/or from de novo steroid synthesis. However, the relative contribution of de novo steroidogenesis to AR-driven cell growth is unknown. METHODS The relative contribution of androgen biosynthetic pathways to activate androgen receptor (AR)-regulated cell growth and expression of PSA, FKBP5, and TMPRSS2 was studied at physiologically relevant levels of adrenal androgen precursors and intermediates of de novo androgen biosynthesis in human prostate cancer cell lines, PC346C, VCaP, and LNCaP. RESULTS In PC346C and VCaP, responses to pregnenolone and progesterone were absent or minimal, while large effects of adrenal androgen precursors were found. VCaP CRPC clones overexpressing CYP17A1 did not acquire an increased ability to use pregnenolone or progesterone to activate AR. In contrast, all precursors stimulated growth and gene expression in LNCaP cells, presumably resulting from the mutated AR in these cells. CONCLUSIONS Our data indicate that at physiological levels of T precursors PC cells can generally convert adrenal androgens, while de novo steroidogenesis is not generally possible in PC cells and is not able to support AR transactivation and PC growth. Prostate 73: 1636–1650, 2013.Keywords
Funding Information
- Erasmus MC
This publication has 58 references indexed in Scilit:
- Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasterideThe Journal of Steroid Biochemistry and Molecular Biology, 2012
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 InhibitorsCancer Research, 2011
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- European cancer mortality predictions for the year 2011Annals of Oncology, 2011
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations, 2009
- Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterolMolecular and Cellular Endocrinology, 2008
- Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implicationsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663Journal of Clinical Oncology, 2003
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990